Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Rettig

Showing results (111-120 of 144) with videos related to

Pageof 15
Sort By:
Cell Reports|October 10, 2023
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancerPreston D Crowell, Jenna M Giafaglione, Anthony E Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate CancerTanya Dorff, Lisa G Horvath, Karen Autio, et al.
Cancer Research|June 8, 2023
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerArian Lundberg, Meng Zhang, Rahul Aggarwal, et al.
JCO Oncology Practice|September 28, 2020
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTCBrittany M Szymaniak, Lauren A Facchini, Veda N Giri, et al.
European Urology|March 15, 2024
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate CancerNicholas G Nickols, Sonny Tsai, Nathanael Kane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2025
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II StudyAmar U Kishan, Luca F Valle, Holly Wilhalme, et al.
European Urology|September 18, 2024
Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate CancerAdam B Weiner, Raag Agrawal, Nicholas K Wang, et al.
Science Translational Medicine|December 6, 2019
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancerYanjing Li, Yiping He, William Butler, et al.
European Urology|May 29, 2020
Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate CancerAmar U Kishan, Tahmineh Romero, Mohammed Alshalalfa, et al.
Trials|July 6, 2021
Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trialNicholas G Nickols, Matthew B Goetz, Christopher J Graber, et al.
Pageof 15

Showing results (111-120 of 144) with videos related to

Sort By:
Pageof 15
Cell Reports|October 10, 2023
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancerPreston D Crowell, Jenna M Giafaglione, Anthony E Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate CancerTanya Dorff, Lisa G Horvath, Karen Autio, et al.
Cancer Research|June 8, 2023
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerArian Lundberg, Meng Zhang, Rahul Aggarwal, et al.
JCO Oncology Practice|September 28, 2020
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTCBrittany M Szymaniak, Lauren A Facchini, Veda N Giri, et al.
European Urology|March 15, 2024
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate CancerNicholas G Nickols, Sonny Tsai, Nathanael Kane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2025
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II StudyAmar U Kishan, Luca F Valle, Holly Wilhalme, et al.
European Urology|September 18, 2024
Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate CancerAdam B Weiner, Raag Agrawal, Nicholas K Wang, et al.
Science Translational Medicine|December 6, 2019
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancerYanjing Li, Yiping He, William Butler, et al.
European Urology|May 29, 2020
Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate CancerAmar U Kishan, Tahmineh Romero, Mohammed Alshalalfa, et al.
Trials|July 6, 2021
Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trialNicholas G Nickols, Matthew B Goetz, Christopher J Graber, et al.
Pageof 15